Free ABFM Family Medicine Exam Prep

ACC/AHA 2017 hypertension thresholds (≥130/80), stage 1 vs stage 2 treatment; ACS management (ASA + P2Y12 + statin + BB); heart failure GDMT (ARNI, BB, MRA, SGLT2); atrial fibrillation rate vs rhythm control, CHA2DS2-VASc and HAS-BLED for DOAC vs warfarin.

ADA 2024 Standards of Care: A1c target <7% individualized, metformin first-line, SGLT2/GLP-1 preferred for ASCVD/HF/CKD, tirzepatide and semaglutide for obesity; thyroid screening and subclinical hypothyroidism; DKA/HHS management; osteoporosis bisphosphonates.

GOLD 2024 COPD A/B/E classification and therapy; GINA 2024 stepwise asthma with ICS-formoterol SMART; pneumonia (CAP) treatment; OSA; smoking cessation pharmacotherapy (varenicline, bupropion, NRT).

GERD, PUD and H. pylori 2022 ACG quadruple therapy; IBD; IBS Rome IV criteria; hepatitis B and C (pangenotypic DAA regimens); nonalcoholic fatty liver; celiac disease; hemochromatosis; diverticulitis; colon cancer screening.

USPSTF grades A/B recommendations: BP screening; CRC screening ages 45-75 (colonoscopy, FIT, or Cologuard); breast cancer mammography ages 40-74 biennial (2024 update); cervical ASCCP; LDCT lung screening ages 50-80 with ≥20 pack-years; AAA ultrasound one-time ages 65-75 in men who ever smoked; statin primary prevention ≥40 years with ≥10% ASCVD risk.

Adult ACIP schedule: influenza annual, Tdap with dose each pregnancy, zoster (Shingrix) ≥50, pneumococcal PCV15+PPSV23 or PCV20 for adults ≥65, RSV shared decision for adults ≥60, HPV through age 26 (shared decision 27-45), COVID-19 updated formulation.

Uncomplicated UTI and pyelonephritis; CAP inpatient vs outpatient; HIV PrEP (tenofovir-emtricitabine) and PEP; STI management (syphilis staging, gonorrhea 500 mg ceftriaxone plus doxycycline for chlamydia); TB latent and active; cellulitis and MRSA.

Osteoarthritis; rheumatoid arthritis early csDMARD/bDMARD; gout acute flare and urate-lowering (allopurinol with prophylaxis); fibromyalgia; low back pain red flags and sciatica; rotator cuff and knee injuries.

Contraception effectiveness tiers and eligibility criteria (CDC U.S. MEC); hormone therapy individualized risk-benefit; abnormal uterine bleeding; PCOS; endometriosis; menopause; prenatal care; breast complaints.

BPH (alpha-blocker, 5-ARI); erectile dysfunction; testosterone deficiency and when to screen for low-T; prostate cancer PSA shared decision ages 55-69 (USPSTF grade C).

Depression (PHQ-9), GAD-7 anxiety, bipolar, adult ADHD, SSRI dosing and serotonin syndrome; substance use (CAGE, AUDIT); opioid use disorder MAT — buprenorphine, methadone, naltrexone; suicide risk; trauma-informed care.

Well-child care and Bright Futures schedule; developmental milestones; ADHD and ASD screening; common pediatric infections; immunizations; childhood obesity and asthma action plans.

Beers criteria 2023 potentially inappropriate medications; falls STEADI assessment; dementia (MMSE, MoCA); delirium CAM; polypharmacy and deprescribing; advance care planning.

Eczema, psoriasis, acne, rosacea; skin cancer recognition (melanoma ABCDE, BCC, SCC); common rashes and procedures; wound care.

CKD KDIGO GFR categories G1-G5 and albuminuria A1-A3; CKD management with ACEi/ARB plus SGLT2; electrolyte disorders; nephrolithiasis.

Headache (migraine, tension, cluster), stroke secondary prevention, seizure first presentation, peripheral neuropathy, concussion, Parkinson disease basics.